The NM_003494.4: c.2811-2A>C variant in DYSF, which is also known as NM_001130987.2: c.2865-2A>C, occurs within the canonical splice acceptor site of intron 26. It is predicted to cause skipping of biologically relevant exon 27/55, resulting in a frameshift and introduction of a premature truncation codon that is expected to lead to nonsense mediated decay in a gene in which loss of function is an established disease mechanism. RNAseq analysis has shown that this variant results in near-complete elimination of normal splicing, resulting in the production of three alternative transcripts with a frameshift and premature truncation (PMID: 36983702) (PVS1_RNA). This variant has been detected in at least 4 unrelated individuals with dysferlinopathy (PMID: 36983702, 26671124, 33927379, 30564623). Of those individuals, two were homozygous (1.0 pt), one was compound heterozygous for the variant and a confirmed pathogenic or likely pathogenic variant (c.1852G>A p.Gly618Arg, 1.0 pt), and one carried a variant classified as at least likely pathogenic in unknown phase (c.5529G>A p.Trp1843Ter, 0.25 pts) (PM3_Strong). At least one patient with this variant displayed a progressive limb girdle pattern of muscle weakness and absent dysferlin expression in skeletal muscle and blood monocytes, which is highly specific for DYSF-related LGMD (PP4_Strong; PMID: 36983702). The variant has also been reported to segregate with LGMD in two affected family members from one family (PMID: 26671124; PP1, capped with PP4_Strong). This variant is absent from gnomAD v2.1.1 and v3.1.2 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 1.0.0; 01/08/2025): PVS1_RNA, PP4_Strong, PM3_Strong, PP1, PM2_Supporting.